CLINICAL TRIALS

EMD Doses First Patient in MDMA Clinical Trial

Next Investors Oct 09, 2023

Today, our biotech Investment, Emryia (ASX: EMD) has successfully dosed its first patient in a Phase 2b trial using MDMA for the treatment of Post Traumatic Stress Disorder (PTSD).

NTI’s clinical trial meets primary endpoints for neurological disease

Next Investors Oct 06, 2023

Our most recent biotech Investment, Neurotech International (ASX:NTI), has just released successful phase I/II trial results for treating a rare childhood neurological disorder called PANDAS/PANS.

Introducing our new Portfolio Addition: Neurotech International (ASX: NTI)

Next Investors Sep 18, 2023

We are excited to announce our latest investment in Neurotech International (ASX: NTI), an early-stage biotech targeting rare neurological disorders in children; the company is primed for three major share price catalysts in the form of clinical trial results over the next 6-12 months, echoing a strategic approach similar to Neuren Pharmaceuticals, which experienced a 1,300% share price rise over three years.

First on the ASX - BOD announces successful outcome for insomnia clinical trial

Wise-Owl Sep 06, 2023

Our investment, BOD Science (ASX: BOD), has successfully demonstrated the statistical efficacy of its 100mg CBD product for treating insomnia in a Phase IIb study. This milestone puts BOD on track to be the first Australian company to offer a CBD-based insomnia treatment over-the-counter.

Microcap Cannabis Stock BOD has two major near term catalysts…

Wise-Owl Jun 26, 2023

BOD Science (ASX:BOD) has shifted gears from slowly growing revenue, in favour of going for a big blue sky approach to delivering shareholder outcomes. With two near term catalysts on the horizon, could this be the time for BOD?

DXB completes Phase III patient recruitment for crucial interim analysis

Next Investors Dec 15, 2022

Our Biotech Pick of the Year, Dimerix Limited (ASX: DXB), has just announced the completion of patient recruitment for the Phase 3 Interim Analysis data. This is a crucial stage in DXB's FSGS clinical trials, helping inch closer to hopefully produce their drug which helps Renal Kidney disease patients.

Potential new use of DXB’s drug in US$2.5 Billion market

Next Investors Jun 08, 2022

Yesterday our 2021 Biotech Pick of the Year, Dimerix (ASX:DXB), announced an agreement with the Australian Centre for Accelerating Diabetes Innovation to commence a clinical trial on Diabetic Kidney Disease expected Q4 2022.

DXB Recruits First Patient, Gets FDA IND Approval

Finfeed Jun 01, 2022

Our 2021 Biotech Pick of the Year, Dimerix (ASX:DXB), yesterday recruited its first patient for its Phase 3 FSGS trial - a big step forward towards our #1 Objective for the company.

DXB Recruits First Patient, Gets FDA IND Approval

Next Investors Jun 01, 2022

Our 2021 Biotech Pick of the Year, Dimerix (ASX:DXB), yesterday recruited its first patient for its Phase 3 FSGS trial - a big step forward towards our #1 Objective for the company.

Tiny Medical Cannabis Stock BOD Has Started Two Clinical Trials - We are Hoping for a Re-rate on Results

Wise-Owl May 20, 2022

BOD has just began two clinical trials, we are hoping for a re-rate on results of these trials. BOD dosed the first patients for the following trials in the last month for Insomnia (Phase 2b) and Long-COVID (Open label).

DXB: Making Strong Progress on “Main Bet,” Side Bet #2 Paused

Finfeed Feb 28, 2022

Our 2021 Biotech Pick of the Year Dimerix (ASX:DXB) released its half year report last Thursday, updating investors on ethics approvals for its Phase III clinical trial for FSGS (a rare kidney disease) and closing in on important milestones for TWO of its Phase III COVID-19 studies.

DXB: Making Strong Progress on “Main Bet,” Side Bet #2 Paused

Next Investors Feb 28, 2022

Our 2021 Biotech Pick of the Year Dimerix (ASX:DXB) released its half year report last Thursday, updating investors on ethics approvals for its Phase III clinical trial for FSGS (a rare kidney disease) and closing in on important milestones for TWO of its Phase III COVID-19 studies.

Creso’s acquisition target Halucenex to extend clinical trials beyond veterans

Finfeed Archived Jun 08, 2021

Creso Pharma's (ASX: CPH) targeted acquisition company Halucenex intends to expand its phase II clinical trial to include non-veterans.

Halucenex forms important partnership as psychedelics space heats

Finfeed Archived May 06, 2021

Creso Pharma Limited (ASX: CPH, FRA:1X8) has today announced that its acquisition target Halucenex Life Sciences Inc. has signed an agreement with Nucro-Technics, a Pharmaceutical Contract Research Organization (CRO) that is a partner to pharmaceutical, biologic, and medical device companies located all over the world.